辛伐他汀和阿托伐他汀对原发性高胆固醇血症的疗效比较  

Comparison of Therapeutic Effects of Simvatatin and Artovastatin on Primary Hypercholesterolemia

作　　者：李晓丽[1] 梅霞[1] 

机构地区：[1]重庆市中山医院心内科,重庆400013

出　　处：《中国药业》2009年第11期68-69,共2页China Pharmaceuticals

摘　　要：目的比较辛伐他汀和阿托伐他汀治疗原发性高胆固醇血症的疗效和安全性。方法将82例患者随机分为辛伐他汀组(42例)和阿托伐他汀组(40例),辛伐他汀剂量为20mg/d,阿托伐他汀剂量为10mg/d,均口服治疗,疗程为2月,治疗前后分别检查血脂及肝、肾功能。结果治疗2月后两组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)比治疗前显著下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)无明显升高(P>0.05),治疗2月后两组间调脂疗效比较无明显差异,且未见明显不良反应。结论辛伐他汀和阿托伐他汀治疗原发性高胆固醇血症疗效好且安全,患者耐受性好。Objective To compare the efficacy and safety between simvatatin and artovastatin in the treatment of primary hypercholesterolemia. Methods 80 patients with primary hypercholesterolemia were randomly divided into the simvatatin group and artovastatin group. The therapy lasted for 2 months in both two groups. The levels of TC, TG, HDL- C, LDL- C, AST, ALT were measured in pre- treatment and post- treat- ment. Results The levels of TC, TG, LDL- C decreased significantly after treatment（ P 〈0.05）. The levels of HDL- C had unobvious increase （P 〉0.05）. There was no significant difference in the therapeutic results between the two groups without serious adverse reaction. Conclusion Both simvatatin and artovastatin have good therapeutic efficacy and safety on the patients with primary hypercholesterolemia.

关 键 词：辛伐他汀 阿托伐他汀 原发性高胆固醇血症 疗效 

分 类 号：R969.4[医药卫生—药理学] R972.6[医药卫生—药学]